A break-in in Enfield this week had touches of Hollywood drama to it, though the booty itself lacked glamo Read More >>

Eli Lilly & Co. (LLY)

Expected next earnings release:

Announcement date: 4/19/2010 - Before Market

Earnings Quarter: Q1

Announc
          
            Read More
            >>
          
        

Eli Lilly & Co. (LLY)

Expected next earnings release:

Announcement date: 4/19/2010 - Before Market

Earnings Quarter: Q1

Announc
          
            Read More
            >>
          
        

19 March 2010 - The launch of type 2 diabetes drug Victoza in the USA by Danish pharma company Novo Nordisk A/S (CPH: NOVO B) is progressing Read More >>

Jeffrey B. Kindler, Chairman and Chief Executive Officer, Pfizer, was elected board chairman of the Pharmaceutical Research and Manufacturers o Read More >>

As part of its continuing efforts to broaden its male sexual health portfolio, Eli Lilly has announced a worldwide licensing agreement with Acrux for Axiron Read More >>

Research and Markets (http://www.researchandmarkets.com/research/a11370/eli_lilly_and_co) has announced the addition of the "Eli Lilly and Co. - Co Read More >>

Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations Read More >>

Acrux has forged a global licensing deal with Eli Lilly. The Australian-listed biotechnology group expects its first profit in 2 Read More >>

An allegedly well-planned burglary yielded pallets of tens of millions of dollars worth of prescription drugs from a Connecticut warehouse, police s Read More >>

Sometime in the early morning Sunday, thieves scaled the walls of the Eli Lilly warehouse on Fres Read More >>

Australian-listed biotechnology firm Acrux has signed a licensing agreement with Eli Lilly valued at as much as $US335m ($A336.1m). It covers the Read More >>

Multinational pharmaceutical company Eli Lilly has signed a worldwide licensing deal with Australian biotechnology firm Acrux for the l Read More >>

Eli Lilly and Company, a US-based pharmaceutical company, has signed an exclusive worldwide license agreement with Acrux Limited, an Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a commu Read More >>

Pharmaceutical products provider Eli Lilly and Company (NYSE:LLY) said on Monday that the company has signed an exclusive worldwide licence agreement w Read More >>

Australian drug developer Acrux Ltd (ASX:ACR) could receive up to US$335 million (A$366.36 million) plus royalties from US-based pharmaceutical Read More >>

Australian drug developer ACRUX LTD (ASX:ACR) has entered into a licence agreement with United States-based pharmaceutical firm ELI LILLY AN Read More >>

Australian drug developer Acrux Ltd (ASX:ACR) has entered into a licence agreement with United States-based pharmaceutical firm Eli Lilly and Com Read More >>

Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worl Read More >>

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABC Read More >>

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: Read More >>

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALK Read More >>

Crown Bioscience, Inc., a preclinical oncology CRO, announced today that Dr. Chuan (Joe) Shih has accepted the position of Execu Read More >>

A division of Eli Lilly & Co. is purchasing the European rights to several Pfizer Inc. animal-health products.

IQPC's 6th Forum on Laboratory Informatics will showcase today's Laboratory Informatics leaders including individuals from John T. Mather Memorial Hospit Read More >>

Research and Markets (http://www.researchandmarkets.com/research/976f21/antiinfectives) has announced the addition of the "Anti-Infectives - Read More >>

Eli Lilly and Company has signed an agreement to acquire the European rights to a portfolio of certain products of Pfizer Animal Hea Read More >>

Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY), today announced that Lilly has signed an agreement to acquire the Read More >>

Transition Therapeutics, Inc., a Canada-based biopharmaceutical company, has acquired the rights to a series of preclinical compound Read More >>

Subscribers to galtstock.com "Long-Term Portfolio" service (membership) invest in solid long-term holdings. Our portfolio is actively managed. Read More >>

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's eff Read More >>

Transition Therapeutics, a biopharmaceutical company, has acquired the rights to a series of preclinical compounds from Eli Lilly and Company in the area of Read More >>

SmarTrend identified a Downtrend for Eli Lilly (NYSE:LLY) on December 10, 2009 at $35.40. In approximately 3 months, Eli Lilly has returned 3.1% Read More >>

3/3/2010-Transition Therapeutics (NASDAQ:TTHI) said early Wednesday that it has acquired the rights to a series of diabetes-related preclinical com Read More >>

The world's two pharmaceutical giants Sanofi-Aventis SA (Euronext Paris: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) Read More >>

Transition Therapeutics Inc. (TSX:TTH) (Nasdaq:TTHI) today announced that it has acquired the rights to a series of preclinical compounds from Eli Read More >>

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NA Read More >>

IQPC's 6th Forum on Laboratory Informatics will showcase today's Laboratory Informatics leaders including individuals from John Read More >>

Riding its successful launch of the Waters(R) ACQUITY UPLC(R) H-Class System incorporating the proven, robust and reliable performance of AC Read More >>

Research and Markets(http://www.researchandmarkets.com/research/bd3a0a/eli_lilly_pipelin) has announced the addition of the "Eli Lilly: Pipeline, P Read More >>

Like thousands of physicians across the United States, Dr. Ajay Chaudhuri gets paid by pharmaceutical companie Read More >>

Senior executives from Eli Lilly and Company and Covance Inc. (NYSE: CVD) announced Friday that the first year of their landmark alliance has Read More >>

Research and Markets (http://www.researchandmarkets.com/research/a9dd3e/eli_lilly_pipelin) has announced the addition of the "Eli Lilly: Pipe Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a commu Read More >>

I am Peter R. Breggin, MD, a psychiatrist in private practice in Washington, DC, for several decades and now in It Read More >>

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 201 Read More >>

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: Read More >>

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS Read More >>